Phoebe Starr

Authored Items
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 in Emerging Therapies
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2020, Vol 13, No 3 in Emerging Therapies
Real-World Healthcare Utilization and Costs Support Broader Use of CAR T-Cell Therapy
Phoebe Starr
TOP - March 2020, Vol 13, No 2 in Value-Based Care
Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy By
Phoebe Starr
TOP - March 2020, Vol 13, No 2 in ASH 2019 Highlights
Improving Access to Genetic Cancer Screening in a Medically Underserved Community
Phoebe Starr
TOP - March 2020, Vol 13, No 2 in ACCC
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
TOP - March 2020, Vol 13, No 2 in Lung Cancer
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives in ESMO
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
Phoebe Starr
TOP - January 2020, Vol 13, No 1 in Lung Cancer
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Phoebe Starr
TOP - January 2020, Vol 13, No 1 in Lung Cancer
Olaparib Improves Outcomes in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
TOP - January 2020, Vol 13, No 1
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
TOP - January 2020, Vol 13, No 1
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives in Lung Cancer
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
TOP - November 2019, Vol 12, No 4 in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives in ESMO, Breast Cancer
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
TOP - August 2019, Vol 12, No 3 in ASCO
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TOP - August 2019, Vol 12, No 3 in ASCO
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 in Geriatric Cancer
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 in Prostate Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with BRCA Mutations
Phoebe Starr
TOP - August 2019, Vol 12, No 3 in Pancreatic Cancer
Darolutamide, New Androgen Receptor Inhibitor, Extends Metastasis-Free Survival in High-Risk Prostate Cancer
Phoebe Starr
TOP - May 2019, Vol 12, No 2 in Prostate Cancer
First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2019, Vol 12, No 2 in Renal-Cell Carcinoma
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 in Breast Cancer
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 in Breast Cancer
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 in Breast Cancer, Immunotherapy
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Leukemia
Selective RET Inhibitor, BLU-667, Hits the Target in Patients with Lung or Thyroid Cancers
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Emerging Therapies
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
TOP - November 2018, Vol 11, No 3 in Breast Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 in Breast Cancer
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Prostate Cancer
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Genitourinary Cancers
Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma
Phoebe Starr
TOP - May 2018, Vol 11, No 1 in Renal-Cell Carcinoma
Venetoclax plus Rituximab New Chemotherapy-Free Option for Chronic Lymphocytic Leukemia
Phoebe Starr
Web Exclusives in Leukemia
A New Combination as First-Line Regimen in Advanced Hodgkin Lymphoma?
Phoebe Starr
Web Exclusives in Lymphoma
Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Lung Cancer
Pembrolizumab Makes Inroads in Sarcoma Subtypes
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Immunotherapy, Online First
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Breast Cancer
Novel Drug “Home Run” for TRK Mutation–Positive Tumors
Phoebe Starr
TOP - November 2017, Vol 10, No 4 in Emerging Therapies
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, Immunotherapy
Enzalutamide Safe for Patients at Increased Risk for Seizure
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Prostate Cancer
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 in AACR News, Conference Correspondent
Reasons for Emergency Department Visits Related to Immune Checkpoint Inhibitor Treatment
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Side-Effects Management, Side-Effects Management
Discontinuing Immunotherapy Because of Adverse Effects May Not Compromise Efficacy
Phoebe Starr
TOP - May 2017, Vol 10, No 2 in Side-Effects Management, Side-Effects Management
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Duloxetine Helps Reduce Aromatase Inhibitor–Associated Joint Pain
Phoebe Starr
TOP - February 2017, Vol 10, No 1 in Breast Cancer
Older Drugs in “New Clothes” Achieve Superior Outcomes
Phoebe Starr
TOP - November 2016, Vol 9, No 4 in Hematologic Cancers
Price of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
TOP - August 2016, Vol 9, No 3 in Conference Correspondent
Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer
Phoebe Starr
TOP - May 2016, Vol 9, No 2 in Genitourinary Cancers
ABCs of Immunotherapy
Phoebe Starr
TOP November 2015 Vol 8 No 4 in Immunotherapy
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
TOP - May 2015, Vol 8, No 2 in Genitourinary Cancers
Venetoclax Moves Forward in Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Novel Agent Effective for the Management of Cancer-Related Cachexia
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Supportive Care
Posttransplant Brentuximab: New Standard of Care for Hodgkin Lymphoma?
Phoebe Starr
TOP - February 2015, Vol 8, No 1 in Hematologic Cancers
Potential New Approach to Treat Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Combination of BRAF and MEK Inhibitors Improves Survival in Advanced Melanoma
Phoebe Starr
TOP - October 2014, Vol 7, No 4 in Skin Cancer
Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Angiotensin System Inhibitors Extend Survival in Patients With Metastatic Renal Cell Carcinoma
Phoebe Starr
TOP - May 2014, Vol 7, No 2 in Genitourinary Cancers
Two-Thirds of Women Experience Musculoskeletal Toxicity on Aromatase Inhibitors and 22.9% Discontinue Therapy
Phoebe Starr
TOP - May 2013, Vol 6, No 2 in Breast Cancer
Proton Beam Therapy: Similar Toxicity to Standard Radiation, at Much Higher Cost
Phoebe Starr
TOP - December 2012 VOL 5, NO 8 in Genitourinary Cancers
Last modified: June 18, 2020